Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC

Prostate cancer (PCa) remains the most diagnosed non-skin cancer amongst the American male population. Treatment for localized prostate cancer consists of androgen deprivation therapies (ADTs), which typically inhibit androgen production and the androgen receptor (AR). Though initially effective, a...

全面介紹

書目詳細資料

Principais autores:	Ralph E. White, Maxwell Bannister, Abderrahman Day, Hannah E. Bergom, Victor M. Tan, Justin Hwang, Hai Dang Nguyen, Justin M. Drake
格式:	Artigo
語言:	Inglês
出版:	Frontiers Media S.A. 2023-06-01
叢編:	Frontiers in Oncology
主題:	prostate cancer enzalutamide SRC kinase inhibitor Synergy androgen receptor phosphorylation
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1210487/full
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!